#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Medulloblastoma recurrent Astrocytoma malignant Chronic cutaneous lupus erythematosus Pyoderma gangrenosum Mucous membrane pemphigoid Crohn's disease Alexander disease Metabolic disorder Squamous cell carcinoma of the vulva Rheumatoid arthritis Congenital growth hormone deficiency Follicular lymphoma stage I Neurodermatitis Acute graft versus host disease in intestine Mucopolysaccharidosis II More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Treatment Angiosarcoma recurrent – Basic Information Hairy cell leukaemia – Life with Disease Isodicentric chromosome 15 syndrome Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Brain stem glioma Optic glioma – Diagnostics Friedreich’s ataxia – Diagnostics Piriformis syndrome – Treatment Erdheim-Chester disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sarilumab Glycine SODIUM IBANDRONATE ZIMISLECEL Methylprednisolone Lepidoglyphus Destructor Oleclumab LYSERGIDE Mebeverine Hydrochloride Metamizole Etripamil Erythromycin Lactobionate Nefopam Eo2317 Zamtocabtagene Autoleucel Cocarboxylase Tetrahydrate Cefotaxime Sodium Mebufotenin Kd050 Cx-039776 More therapies…

    Learn about Your Condition

    Hip arthroplasty Skin angiosarcoma Anal incontinence Vasoplegia syndrome Endocarditis enterococcal Breast cancer Iron deficiency Rhabdomyosarcoma Stress VEXAS syndrome Muscle injury Malignant melanoma stage III Lymphocytic leukaemia Rectal cancer Perineal injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant peritoneal neoplasm

  • Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Paclitaxel
    Italy

  • Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Sodium Thiosulfate
    • Cisplatin
    Belgium France

  • Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

    Not recruiting

    3 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Oregovomab
    Belgium Czechia Hungary Italy Spain

  • Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Farletuzumab Ecteribulin
    • Topotecan
    • Doxorubicin Hydrochloride
    Belgium Italy Spain

  • Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Raludotatug Deruxtecan
    • Topotecan
    Czechia Finland France Germany Greece Italy +3
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!